Figure 1.

Endogenous and Secretory Overexpression of ANXA3 Is Strongly Associated with HCC Pathogenesis

(A) Relative ANXA3 expression in sorted CD133 subsets isolated from HCC cells and clinical samples by qPCR. Results represent mean ± SD of duplicate wells in three independent experiments.

(B) Western blot showing expression of ANXA3 in sorted CD133 subsets isolated from HCC cells.

(C) Secretory ANXA3 expression levels in sorted CD133 subsets isolated from HCC cells as detected by ELISA.

(D) Dual-color IF images of CD133 (red) and ANXA3 (green) in Huh7. Nuclei stained with DAPI (blue).

(E) Western blots showing expression of CD133 and ANXA3 in a panel of liver cancer cell lines.

(F) Western blot showing expression of ANXA3 in HCC (T) and matched non-tumor liver (N) specimens from six individual patients. Association between tumor stage and ANXA3 overexpression in HCC. ^∗p < 0.05. Results represent mean ± SD from three independent experiments.

(G) Boxplots showing expression of ANXA3 in the sera collected from healthy individuals (normal), HBV carriers (HBV+), patients with liver cirrhosis, and patients with either early HCC (I & II) or advanced HCC (III & IV). Results represent mean ± SD of duplicate wells in three independent experiments.

(H) ROC curve analysis of the sensitivity and specificity of using AFP, ANXA3, or a combination of both for HCC diagnosis. Summary of ROC curve analysis with area under the curve (AUC) and 95% CI values.

See also Figure S1.